Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L P Martin

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Gynecologic Oncology|December 6, 2011
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaH J Mackay, R J Buckanovich, H Hirte, et al.
Investigational New Drugs|January 28, 2014
Phase II trial of vorinostat in advanced melanomaN B Haas, I Quirt, S Hotte, et al.
British Journal of Cancer|September 22, 2012
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumoursL P Martin, M F Kozloff, R S Herbst, et al.
British Journal of Cancer|September 20, 2012
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursM F Kozloff, L P Martin, M Krzakowski, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Gynecologic Oncology|December 6, 2011
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaH J Mackay, R J Buckanovich, H Hirte, et al.
Investigational New Drugs|January 28, 2014
Phase II trial of vorinostat in advanced melanomaN B Haas, I Quirt, S Hotte, et al.
British Journal of Cancer|September 22, 2012
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumoursL P Martin, M F Kozloff, R S Herbst, et al.
British Journal of Cancer|September 20, 2012
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursM F Kozloff, L P Martin, M Krzakowski, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Pageof 3